The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Eli Lilly’s diabetes drug Mounjaro has become the world’s top-selling medication, surpassing Merck’s cancer therapy Keytruda. Lilly’s performance compounded when Mounjaro and weight-loss drug Zepbound ...
Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer ...
For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.
The US Food and Drug Administration has approved pembrolizumab (Keytruda, Merck), as well as its subcutaneous formulation pembrolizumab and berahyaluronidase (Keytruda Qlex, Merck), in combination ...
What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute “We are honored to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results